Has Glenn Wortmann, MD received payments from drug or device companies?

Yes. Drug and device makers reported $7,256 in general payments to Glenn Wortmann, MD across 10 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Glenn Wortmann, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Glenn Wortmann, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Glenn Wortmann, MD

Infectious Disease · Washington, DCNPI 1518053529

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $6,450 of the $7,256 with a category attached, or 88.9%. Astellas Pharma US Inc accounts for 99.1% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2019 at $7,192 and has fallen 99.5% since, to $35 in 2025.

$7,256in general payments, 2019–2025

Across 10 payments — averaging $725.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Astellas Pharma US Inc$7K
Caris MPI, Inc.$35
Johnson & Johnson$28

$596,513in research payments, 2019–2025

Across 114 payments — averaging $5232.57 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Regeneron$210K
Dompe Farmaceutici S.p.a.$108K
Vanda Pharmaceuticals Inc.$96K
Gilead$73K
AstraZeneca$61K
Pfizer$49K

What the payments were for

Speaking & faculty fees$6,45089%
Travel & lodging$5618%
Food & beverage$2163%
Education$280%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Astellas Pharma US Inc	8	$7,192
Caris MPI, Inc.	1	$35
Johnson & Johnson	1	$28

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

CRESEMBA$1,505

How this compares

$7,256 in reported general payments places this provider in the 85th percentile of 74 infectious disease providers in District of Columbia.

See all infectious disease providers in District of Columbia →

Medicare billing

Part B allowed, 2024

$57,832

Medicare patients

221

Services billed

530

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala	97	$393,487
TriumeqAbacavir/Dolutegravir/Lamivudi	21	$86,912
OdefseyEmtricitab/Rilpiviri/Tenof Ala	22	$83,731
CabenuvaCabotegravir/Rilpivirine	13	$77,456
PrezcobixDarunavir/Cobicistat	30	$72,597
DovatoDolutegravir Sodium/Lamivudine	23	$62,355
GenvoyaElviteg/Cob/Emtri/Tenof Alafen	14	$55,942
IsentressRaltegravir Potassium	13	$25,539
MicafunginMicafungin Sodium	19	$6,109
Emtricitabine-Tenofovir DisopEmtricitabine/Tenofovir (Tdf)	11	$1,362
ValacyclovirValacyclovir Hcl	26	$1,072
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav	11	$2

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
Johnson & JohnsonPrezcobix	$28	$72,59730 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 74 infectious disease providers in District of Columbia.

Other infectious disease in Washington

Jesse GoodmanWashington$1.8M
Theo HodgeWashington$1M
Robert GasserWashington$922K
Princy KumarWashington$270K
Jose ChavezWashington$254K
Linda NabhaWashington$60K
Gebeyehu TeferiWashington$25K
Jose BordonWashington$12K
Rebecca KumarWashington$12K
Jeffrey MurrayWashington$8K

See the full list for District of Columbia →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →